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Relapse is a major challenge in the successful treatment of childhood acute lymphoblastic leukemia (ALL).
Despite intensive research efforts, the mechanisms of ALL relapse are still not fully understood. An under-
standing of the molecular mechanisms underlying treatment outcome, therapy response and the biology
of relapse is required. In this study, we carried out a genome-wide microRNA (miRNA) microarray analysis
to determine the miRNA expression proﬁles and relapse-associated miRNA patterns in a panel of matched
diagnosis–relapse or diagnosis–complete remission (CR) childhood ALL samples. A set of miRNAs differen-
tially expressed either in relapsed patients or at diagnosis compared with CR was further validated by quan-
titative real-time polymerase chain reaction in an independent sample set. Analysis of the predicted functions
of target genes based on gene ontology ‘biological process’ categories revealed that the abnormally
expressed miRNAs are associated with oncogenesis, classical multidrug resistance pathways and leukemic
stem cell self-renewal and differentiation pathways. Several targets of the miRNAs associated with ALL
relapse were experimentally validated, including FOXO3, BMI1 and E2F1. We further investigated the
association of these dysregulated miRNAs with clinical outcome and conﬁrmed signiﬁcant associations
for miR-708, miR-223 and miR-27a with individual relapse-free survival. Notably, miR-708 was also found to
be associated with the in vivo glucocorticoid therapy response and with disease risk stratiﬁcation.
These miRNAs and their targets might be used to optimize anti-leukemic therapy, and serve as novel targets
for development of new countermeasures of leukemia. This fundamental study may also contribute to estab-
lish the mechanisms of relapse in other cancers.
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Childhood acute lymphoblastic leukemia (ALL) is the most
common childhood malignancy worldwide (1,2). Despite sub-
stantial improvements in therapy, the number of cases in
which relapse occurs is still higher than the number of
newly diagnosed cases in other childhood cancers, and the
outcome after relapse is generally poor (1,2). Therefore,
there is a strong need to develop novel prognostic factors to
predict relapse and therapeutic strategies. To this end,
insight into the molecular mechanisms underlying treatment
outcome, therapy response and the biology of relapse is
required.
Several mechanisms for leukemia relapse have been
reported in recent years. A number of studies have proposed
that ALL relapse results from residual leukemic cells that
have survived after therapy (3–6). Other groups have sug-
gested that relapse could result from either the acquisition of
a resistant phenotype in response to therapy and subsequent
selection or the selection of an inherently resistant subclone
initially undetected at diagnosis but present in low numbers
(7). Recent work has also shown that ALL relapse is character-
ized by genomic alterations involving numerous genes, and
molecular abnormalities have been identiﬁed in matched diag-
nosis–relapse pairs of childhood ALL samples through DNA
microarray studies (8–11). These studies have provided
novel biomarkers with potential use for diagnosis and tailored
therapy in pediatric acute leukemia. However, it is clear that
the pathways involved in ALL relapse are complicated, and
the mechanisms that underlie relapse are largely elusive.
A class of small noncoding RNAs ranging from 19 to 25
nucleotides termed microRNAs (miRNAs) was shown to regu-
late gene expression at transcriptional or post-transcriptional
levels (12). Widespread roles of miRNAs in diverse molecular
processes driving the initiation and progression of various
tumor types are known. The ﬁrst evidence that miRNAs
may be involved in the regulation of hematopoiesis came
from a report that miRNAs modulate hematopoietic lineage
differentiation (13), and subsequent studies have indicated
that miRNAs indeed play a key role in cancer diagnosis and
therapy (14). Altered miRNA expression has been observed
in leukemia (15–20), and despite the link of miRNAs to child-
hood ALL development and progression and clinical therapy
is revealed (18), little is known about the expression patterns
and functions of miRNAs at relapse. Several studies have indi-
cated that miRNAs respond to glucocorticoids (GC) (19) and
play a role in multidrug resistance (21), suggesting a function-
al role for miRNAs associated with relapse in drug-resistant
leukemic cells. Other groups have proﬁled miRNA expression
in B-precursor ALL (B-ALL) and T-precursor ALL (T-ALL)
(16,18); however, many of these studies focused primarily
on the initial diagnosis. Dysregulated miRNAs from pairwise
comparisons of matched diagnosis and relapse have not been
reported, and their functional relevance in relapse has not
been investigated.
In this study, we used genome-wide miRNA microarrays to
analyze matched diagnosis–relapse samples in an attempt to
gain insight into the biology of relapse in childhood ALL
and investigate the possible contributions of miRNA deregula-
tion. For comparison, matched diagnosis–complete remission
(CR) samples were also studied. An additional 163 pediatric
patients were used as a validation set to conﬁrm the expression
of differential miRNAs. A set of abnormally expressed
miRNAs was found to be associated with oncogenesis, classic-
al multidrug-resistance pathways and leukemic stem-cell self-
renewal and differentiation pathways using gene ontology
(GO) ‘biological process’ classiﬁcations and experimental val-
idation. We detected the dysregulated expression of miRNAs,
including miR-708, miR-223 and miR-27a, in childhood ALL
relapse, and these miRNAs could be used to predict the
relapse-free survival (RFS) of leukemia in a representative
cohort of ALL patients with a 3-year follow-up. These
results point to speciﬁc miRNA pathways that might be
exploited for use as both prognostic indicators and novel
targets for therapy.
RESULTS
miRNA expression analysis of paired samples indicates a
relapse-associated miRNA pattern in childhood ALL
In an effort to identify the biological mechanisms of ALL
relapse, we selected 18 matched-pair samples that had sufﬁ-
cient cell material available at diagnosis, relapse or CR and
extracted enough total RNA to perform miRNA microarray-
based gene-expression proﬁling. The data from 41 microarrays
(8 pairs of diagnosis–relapse samples, 10 pairs of diagnosis–
CR samples and 5 healthy controls) were summarized into
probe set expression values and clustered. Unsupervised hier-
archical clustering based on the expression of these miRNA
sets identiﬁed three groups that coincided precisely with
disease at diagnosis, at relapse and in CR when compared
with healthy control; abnormally regulated miRNAs were pre-
sented in Supplementary Material, Figure S1.
Using SAM analysis, we identiﬁed probe sets that were dif-
ferentially expressed at relapse compared with initial diagnosis
or CR in the match-paired ALL cases. In total, 70 of 576
miRNAs were abnormally regulated in samples at relapse or
CR compared with initial diagnosis of the same patients. For
samples at relapse versus diagnosis, the most differentially
expressed miRNAs included miR-223, miR-23a, let-7g,
miR-181, miR-708 and miR-130b, while for the comparison
of CR samples with diagnostic samples, miR-27a, miR-223,
miR-23a, miR-181 and miR-128b have differential expression
pattern. The results also showed that miRNA expression
proﬁle of the CR samples was signiﬁcantly distinct from the
relapse group (Fig. 1A and Supplementary Material,
Table S1). Among these miRNAs, miR-223, miR-23a and
let-7g were downregulated with higher fold changes in the
relapse samples compared with the samples of the same
patients at CR, whereas miR-181 family, miR-708 and
miR-130b were upregulated with higher fold changes in the
relapse samples. Moreover, miR-708 was the most upregu-
lated miRNA in the relapse samples, whereas miR-223 was
signiﬁcantly downregulated at relapse, suggesting that
miR-708 and miR-223 may have important roles in pediatric
ALL relapse. Other miRNAs, such as miR-27a and
miR-128b, whose expressions are downregulated in relapse
compared with CR, may be involved in the progress of
relapse caused by drug resistance after chemotherapy,
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than diagnosis when compared with CR and miR-181 whose
expression is much higher in relapse than diagnosis when
compared with CR might have a complicated role in leukemo-
genesis and relapse. To conﬁrm the differential expression
pattern, we performed a quantitative real-time polymerase
chain reaction (qRT-PCR) assay to validate the expression
of miR-23a, miR-223, let-7g, miR-181a, miR-181b,
miR-128b, miR-27a, miR-708 and miR-130b in the samples
at initial diagnosis and relapse as well as CR as shown in
Supplementary Material, Figure S2. The qRT-PCR results
largely conﬁrmed the microarray data except for let-7g,
whose expression did not show signiﬁcantly different among
three groups.
The qRT-PCR results showed that miR-708, miR-223,
miR-27a and miR-128b were differentially expressed in
patients either in relapse or at original diagnosis compared
with those in CR (P , 0.01). Notably, miR-708 and miR-223
have the most signiﬁcant differences between the relapse and
CR patients. Thus, we further detected their expression in a
large sample set, which consisted of unmatched bone marrow
samples at initial diagnosis (n ¼ 104) and relapse (n ¼ 29) as
well as CR (n ¼ 30) (Fig. 1B–E), suggesting that these mole-
cules could have functional relevance in disease recurrence.
For example, the expression of miR-708 was higher in relapse
while lower in CR compared with diagnosis, implying that
miR-708 might control a cancer-related factor in the progress
of leukemia (Fig. 1B). In contrast, the expression of miR-223
was higher in CR, suggesting an oncogene-like factor or
drug-resistant factor in the progress of leukemia was regulated
by miR-223 (Fig. 1C). Result of qRT-PCR indicated that
miR-27a presented a similar expression pattern as miR-223
(Fig. 1D). In a previous work, we have demonstrated that
miR-27a could directly regulate expression of a drug-resistant
factor,P-glycoproteinandoverexpressionofmiR-27aincreased
sensitivity of leukemia cells to doxorubicin, indicating that
downregulated miR-27a might be involved in relapse via indu-
cing drug resistant of leukemia (21). MiR-128b was reported to
promote drug resistance in many cancers, including ALL
(22,23). Here, we also found that the expression of miR-128b
was higher in relapse and at diagnosis compared with CR, im-
plying that this miRNA might control a tumor suppressor in
the progress of leukemia (Fig. 1E).
Dysregulated miRNAs target key factors involved in ALL
progression and relapse
The temporal variation in miRNA expression levels at diagno-
sis and relapse suggested that miRNAs control the expression
of key proteins underlying mechanisms leading to leukemo-
genesis and relapse. To elucidate the pathogenic role of the
signiﬁcantly differentially expressed miRNAs at diagnosis
and relapse (fold change . 2.0 and P , 0.001), a total of 46
miRNAs were selected for targets analysis. The targets were
predicted by PicTar, TargetScan and miRanda (24) and 395
genes were predicted as the targets of miRNAs output by
Figure 1. Cluster analysis of miRNA expression of paired relapse and/or CR samples in childhood ALL and validation with qRT-PCR. (A) The 70 top-ranked
differentially expressed miRNAs in pediatric ALL; the average miRNA level at diagnosis was set as 1. The fold changes of individual miRNA at diagnosis,
relapse or CR, against average miRNA level at diagnosis were clustered in this tree distribution. (B–E) Differential expressions of miRNAs at diagnosis,
relapse or CR were validated with qRT-PCR. (B) miR-708 (C) miR-223 (D) miR-27a and (E) miR-128b. Normal: healthy control; diagnosis: samples at
initial diagnosis; CR: samples in ﬁrst complete remission; relapse: samples at relapse.
Human Molecular Genetics, 2011, Vol. 20, No. 24 4905Figure 2. GO analysis. Clustering of over-represented GO classes in predicted targets of 46 differential miRNAs (fold change . 2.0 and P , 0.001). All genes
with statistically overrepresented GO annotations were included (P , 0.001).
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46 miRNAs, there are 5 miRNA families including miR-23,
miR-181, let-7, miR-15 and miR-320. Because different
members in a family share the same functions, thus only one
member representing the family was shown in the cluster, as
a result only 35 miRNAs presented (Fig. 2, on the top). By
examining the signiﬁcant GO ‘biological process’ classiﬁca-
tions that were over-represented among the putative targets
genes of the differentially expressed miRNAs, we analyzed
the functional annotation for predicted target sets. Clustering
of the over-represented GO classes in predicted targets of dys-
regulated miRNAs showed that the most signiﬁcant GO terms
were genes involved in macromolecular metabolic process,
biosynthetic process and transcription regulation (Fig. 2).
Notably, a number of miRNAs were related to drug transport,
multidrug resistance or regulation of cellular biosynthetic
process (Fig. 2, blue), and these annotated functions might
be associated with miR-124, miR-145, miR-155 and
miR-223 etc. Another cluster of signiﬁcant GO terms was
associated with stem-cell development and differentiation
(Fig. 2, red), and these genes might be correlated with
miR-27a, miR-128b, miR-29a, miR-18a etc. To evaluate the
functional signiﬁcance of the miRNA target genes, we also
used BiNGO (Biological Networks Gene Ontology) (25)t o
construct a hierarchical ontology tree in Cytoscape (26), as
shown in Figure 3. The color represents enrichment signiﬁ-
cance—the deeper the color on a color scale, the higher the
enrichment signiﬁcance. White color nodes are not enriched
but show the hierarchical relationship among the enriched
ontology branches. It was shown that the nodes representative
genes response to chemical stimulus or drug as well as to
stem-cell differentiation have a deeper color, implying that
relapse could arise from activation of drug-resistance related
genes or silent cancer stem-cell loci by miRNAs after diagno-
sis due to induction of resistance during chemotherapy.
To further get insights into the biological pathways of the
dysregulated miRNAs mentioned above, an mRNA–miRNA
network by analysis of mRNA as opposed to miRNA was con-
structed to search the function of target genes involved in leu-
kemogenesis and leukemia relapse. Dysregulated miRNAs and
their targets or potential target mRNAs including the already
known and our prediction were connected in Supplementary
Material, Figure S3. Target prediction showed that BMI1,a
transcription factor necessary for hematopoietic stem cell
(HSC) and leukemia stem-cell self-renewal (27,28), is the
putative target of both miR-27a and miR-128b, while E2F1,
a master cell-cycle regulator, is the target of miR-223 (29).
In addition, FOXO3, a forehead transcription factor that is crit-
ical for HSC self-renewal and mediates the initial apoptotic
response (30–32), contained the conserved miR-708 response
elements (MRE) in its 3′ untranslated terminal region (UTR).
To conﬁrm the direct effects of these miRNAs, we fused the
3′UTR sequences of FOXO3, BMI1 and E2F1, each contain-
ing putative binding sites to their respective miRNA, to a
Figure 3. Relapse-associated miRNA targets enrichment network based on GO molecular functions and biological processes. Signiﬁcantly overrepresented GO
terms based on GO molecular functions and biological processes were visualized in Cytoscape. The size of a node is proportional to the number of targets in the
GO category. The color represents enrichment signiﬁcance—the deeper the color on a color scale, the higher the enrichment signiﬁcance. White color nodes are
not enriched but show the hierarchical relationship among the enriched ontology branches.
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with the corresponding constructs, we found that all three
miRNAs signiﬁcantly repressed luciferase activity compared
with miR-negative control (NC) (scrambled oligonucleotides)
and mock (water) (Fig. 4A and B). Deletion of each seed
sequence binding with the miRNAs showed that all contribu-
ted to the regulation of these transcripts, although not to the
same degree (Fig. 4A and B). Cotransfection of the miR-708
mimics and the luciferase vector with the 3′UTR of FOXO3
into HEK-293T cells reduced luciferase activity to 40% com-
pared with a miR-NC. Cotransfection of the BMI1 luciferase
constructs with the precursor of miR-27a and cotransfection
of the E2F1 luciferase constructs with the precursor of
miR-223 reduced luciferase activity to 60 and 22%, respect-
ively, compared with controls. To further determine whether
these genes are regulated by their corresponding miRNAs,
we performed both miRNA overexpression and knockdown
experiments in the Jurkat cell, a T-ALL cell line and examined
the expressions of FOXO3, BMI1 and E2F1, respectively. As
shown in Figure 4C, when transfected with the miRNA
mimics (small molecular mimics of mature miRNAs) into
the Jurkat cell, miR-708, miR-27a and miR-223 signiﬁcantly
decreased the expression levels of the FOXO3, BMI1 and
E2F1 proteins, respectively, compared with miRNA negative
control (miR-NC, miRNA negative control, scrambled oligo-
nucleotides). Alternatively, when the Jurkat cells were trans-
fected with the miRNA inhibitors (antisenses, anti-miRs),
the protein expression increased. We further examined the
mRNA expression of FOXO3, BMI1 and E2F1 in patient
samples. The results indicated that expressions of these
miRNAs have an inverse correlation with the corresponding
target gene expression (Fig. 4D). Taken together, these data
Figure 4. miRNAs dysregulated speciﬁcally at relapse repress expression of key proteins. (A) Schematic representation of the interaction of miRNA with the
3′UTR of its corresponding targets. The MRE in the 3′UTR of human were predicted by TargetScan and miRBase target. Each predicted MRE 3′UTR was
inserted into a psiCHECK-2 vector immediately downstream from the Renilla luciferase gene. (B) Luciferase reporter assays analyzing the putative targets
of the three miRNAs. HEK-293T cells were co-transfected using Lipofectamine 2000 with psiCHECK-2 plasmids with the 3′UTR of target genes-wt or the
target genes-mut and miRNA mimics or mimics negative control (mimics-NC). Fireﬂy luciferase activity was normalized to renilla luciferase activity, and
the results were expressed relative to the control (miRNA mimics/mock). (C) Jurkat cells were transfected with 100 nM miRNA inhibitor-NC or miRNA inhibitor
and mimics-NC or miRNA mimics, respectively; miR-708 (left panel), miR-27a (middle panel) and miR-223 (right panel). Cells lysates were prepared for
western blotting with antibodies against FOXO3, BMI1 or E2F1. GAPDH expression served as loading controls. (D) Differential expressions of FOXO3,
BMI1 or E2F1 mRNA in diagnosis samples with different miRNA expressions were measured by qRT-PCR, GAPDH expression served as loading controls.
4908 Human Molecular Genetics, 2011, Vol. 20, No. 24support a direct effect of these miRNAs on their target at both
transcription and post-transcription levels.
Speciﬁc miRNA expression is associated with the risk of
relapse in childhood ALL
The above results indicated a speciﬁc pattern of miRNA
expression and the biological pathway associated with leuke-
mia relapse. We then asked whether these miRNAs could
serve as the biomarkers for prediction of leukemia relapse?
To address this issue, we analyzed the expressions of
miR-708, miR-27a, miR-223 and miR-128b with qRT-PCR
from a cohort of 70 newly diagnosed childhood ALL patients.
These miRNAs were chosen because of their differential ex-
pression pattern and their targets involved in biological path-
ways related to drug resistance or leukemic stem-cell
maintenance and differentiation. The patterns of these
miRNAs expressions were compared with clinical outcome
of childhood ALL in a 36-month follow-up survey. We
found that the levels of miR-708 (P ¼ 0.0483), miR-223 (P
¼ 0.0079) and miR-27a (P ¼ 0.0024) at diagnosis were corre-
lated to RFS (Fig. 5A–C). To visualize the association of
these miRNAs with outcome, the discrete variables of each
miRNA at diagnosis were clustered into two groups, high
and low expression according to the median expression in
the full set of 70 samples. The Kaplan–Meier survival plot
was generated based on these two groups of each miRNA.
Patients with high miR-708 expression at diagnosis had a
higher RFS rate (84.0%) compared with patients in the low ex-
pressional group, which had 66.2% of RFS. Similar correla-
tions were observed in miR-223 of which a higher RFS rate
was correlated with high expression cluster (87.6%) compared
with 63.3% of RFS in low expression group, and miR-27a,
where the RFS rate in the high expression group was 84.8%
compared with 65.6% in the low expression group. No clear
correlation between the level of miR-128b at diagnosis and
RFS was identiﬁed (P ¼ 0.7152) (data not shown).
To determine further whether miRNA expression proﬁling
could be used to predict ALL relapse, we validated the predict-
ive values obtained from miRNA proﬁling. The speciﬁcities of
miR-708,miR-223andmiR-27awere67.9,74.7and69.4%, re-
spectively, and the sensitivities of these miRNAs were 55.9,
58.1 and 56.4%, respectively. Because the predictive objects
of these three miRNAs did not completely overlap one
another, we postulated that a combination of two or three
miRNAs might improve the predictive value. As expected, the
speciﬁcity of a combination of these three miRNAs reached
as high as 91.4%, and the sensitivity of a combination of at
least two of the three miRNAs reached 90.5%. Our results indi-
catethat the useofamiRNAproﬁle couldyield ahighaccuracy
of predicting pediatric ALL relapse.
Next, we used univariate Cox regression to evaluate the
impact of these data. Both miR-708 and miR-223 were
found to be univariate predictors (P ¼ 0.011 and P ¼ 0.004,
respectively). However, miR-27a was failed in univariate
Cox regression analysis due to high variance (P ¼ 0.135). A
multivariate Cox regression analysis was also assessed to
evaluate the impact of these miRNAs at diagnosis on RFS.
The frequently used clinical prognosis factors [age, immuno-
phenotyping, prednisone treatment response, white blood cell
(WBC) count before chemotherapy, remission status after
15-day and 33-day chemotherapy and the fusion gene BCR–
ABL and MLL] were included in this analysis (Table 1).
Patients with low miR-223 expression had a 24.22-fold
higher risk of relapse (P ¼ 0.001, 95% CI 3.73–157.28).
Remission rate after 33-day chemotherapy, immunophenotyp-
ing, age and MLL positive were also signiﬁcant predictors (P
¼ 0.002, P ¼ 0.002, P ¼ 0.048 and P ¼ 0.019, respectively).
Results indicated that miR-223 expression at initial diagnosis
is an independent and reliable predictor for relapse. Our
Figure 5. Dysregulated miRNAs at diagnosis can predict RFS. The represen-
tative RFS curves for miR-708 (A), miR-27a (B) and miR-223 (C) were mea-
sured by qRT-PCR. Statistical differences between curves were calculated
using the log-rank test.
Human Molecular Genetics, 2011, Vol. 20, No. 24 4909analyses inferred that miR-708 expression at diagnosis is also
a reliable predictor but not an independent one.
Upregulation of miR-708 is associated with in vivo GC
response and disease risk aggressiveness in childhood ALL
GCs are clinically used to treat childhood ALL and other
lymphoid malignancies (33). Poor response to 7-day
monotherapy with the GC prednisone is one of the strongest
predictors of adverse outcomes in the treatment of childhood
ALL (33,34). Despite rapid advances in biomedical technol-
ogy facilitating the development of molecular diagnostic
assays, more reliable predictor for GC resistance in ALL is
still eagerly needed. As mentioned above, special miRNAs
pattern could serve as the biomarkers to predict the relapse
of childhood ALL. Can they also as a reliable stratiﬁcation
factor contribute to predict GC resistance? To address this
question, we retrospectively analyzed the outcome of ALL
patients with initial response to prednisone treatment data
available. Therapeutic effect was deﬁned as a reduction in leu-
kemic blasts in the peripheral blood to below 1000 per ml after
7 days of treatment with prednisone. The 7-day window of
prednisone monotherapy (before the combination chemother-
apy) used to ascribe pediatric patients with ALL to either
the non-high-risk (prednisone good response, PGR) or high-
risk (prednisone poor response, PPR) categories and provided
an opportunity to correlate the miRNA expression levels with
the in vivo GC (prednisone) response. The miR-708, miR-223
and miR-27a were analyzed with the specimens at initial diag-
nosis through all the groups. The miR-708 expressions signiﬁ-
cantly distributed in different patterns between the prednisone
response groups. Highly expressed miR-708 was detected
from specimens in PGR, while lower miR-708 level appeared
in PPR (P ¼ 0.0004), indicating miR-708 level before chemo-
therapy was highly predictive of GC response (Fig. 6A).
However, despite some patterns also obtained from miR-27a
and miR-223, there were no statistical signiﬁcances between
the two groups (P ¼ 0.2933 for miR-27a and P ¼ 0.8963 for
miR-223, Supplementary Material, Figs S4A and S5A).
We then clustered patients into three risk stratiﬁcation groups,
standard risk (S), middle risk (M) and high risk (H), based on
well-known risk factors, i.e. age, cytogenetics, remission
status, response to induction therapy and survival outcomes
according to the risk stratiﬁcation system from ALLIC BFM
2002. We found that the patients in both standard risk and
middle risk had higher expressed miR-708, while the high-risk
patients displayed a signiﬁcantly low level of miR-708 (H
versus S: P ¼ 0.0040; H versus M: P ¼ 0.0280). There were
no signiﬁcant difference in miR-708 expression levels
between standard risk and middle risk groups (P ¼ 0.7444)
(Fig. 6B). Similar pattern was not observed in either expression
of miR-27a or miR-223 at patient groups (Supplementary Ma-
terial, Figs S4B–E and S5B–E). In this study, we also found
that the miR-708 expression at initial diagnosis differed
among the four immunophenotypes, pro-B-ALL, pre-B-ALL,
common ALL and T-ALL (Fig. 6C). The T-ALL phenotype,
commonly recognized to correspond with higher risk of
relapse, had the lowest miR-708 expression levels, implying
lower miR-708 before therapy correlating to high relapse risk
in patients received chemotherapy.
Correlation of miR-708 level before chemotherapy with
other risk factors was also evaluated in this study. Patients
with high miR-708 expression at diagnosis had a higher
overall survival rate (P ¼ 0.0174, Supplementary Material,
Fig. S6) compared with patients in the low expressional
group. WBC count at diagnosis of .20 × 10
9 per l is consid-
ered factor affecting 5-year survival rates of ALL patients. We
therefore studied whether where was the negative correlation
between miR-708 level and WBC count before chemotherapy.
As shown in Figure 6D, miR-708 expression was lower in the
higher WBC group (.20 × 10
9 per l) compared with the
lower WBC group (P ¼ 0.0355), giving another evidence of
that patients whose miR-708 lower before therapy has higher
relapse potential. We also noted that patients with the
BCR–ABL fusion gene and patients older than 12 years,
who are considered at higher risk for relapse, also have
lower miR-708 expression (P ¼ 0.0420 and P ¼ 0.0030,
respectively, data not shown). Notably, patients who exhibited
a better remission status after 15-day chemotherapy (,5%
blasts) had higher miR-708 expression than those in an un-
favorable remission status (.25% blasts) (P ¼ 0.0124)
(Fig. 6E). In addition, patients with a better remission status
after 33-day chemotherapy (,5% blasts) also had a higher
miR-708 expression than those at a worse remission status
(≥5% blasts) (P ¼ 0.0177, data not shown), suggesting that
low miR-708 expression levels could predict a higher risk
for leukemogenesis or relapse.
DISCUSSION
Relapse following initial chemotherapy remains a barrier to
survival in  20% of children suffering from ALL and is,
therefore, of great interest to physicians and researchers.
Despite intensive research efforts, the molecular mechanisms
underlying ALL relapse are still not fully understood. In this
study, we initiated a genome-wide miRNA microarray
Table 1. Univariate and multivariate Cox regression analysis
Factor (categories) Hazard ratio (95% CI) P-value
Univariate Cox regression
Age (10-year increase) 0.041
Immunophenotyping (T-ALL) 0.340
Prednisone treatment response (PPR) 0.021
WBC before chemotherapy (20 × 10
9
per liter increase)
0.070
15-day remission status
a (blast ≥ 25%) 0.009
33-day remission status
a (blast ≥ 5%) ,0.001
BCR–ABL (positive) 0.002
MLL (positive) 0.759
miR-708 (low expression) 0.011
miR-223 (low expression) 0.004
miR-27a (low expression) 0.135
multivariate Cox regression
Age (10-year increase) 3.30 (1.01 to 10.77) 0.048
Immunophenotyping (T-ALL) 11.26 (2.45 to 51.69) 0.002
33-day remission status (≥5%) 6.22 (2.00 to 19.40) 0.002
miR-223 (low expression) 24.22 (3.73 to 157.28) 0.001
MLL 26.79 (1.71 to 420.28) 0.019
aDuring induction treatment.
4910 Human Molecular Genetics, 2011, Vol. 20, No. 24analysis in paired diagnosis–relapse and/or CR bone marrow
samples of childhood ALL. There were two advances in this
study. First, we identiﬁed a differential miRNA pattern
between relapse and CR patients that included miR-708,
miR-223 and miR-27a. In addition, miR-708 was upregulated
in relapse, whereas both miR-223 and miR-27a were highly
expressed in patients during CR, suggesting that these dysre-
gulated miRNAs play important roles in controlling disease
progression—namely, in the relapse of patients who had
been in remission.
Secondly, to elucidate the fundamental roles of these
relapse-associated miRNAs, we analyzed the putative gene
targets of these dysregulated miRNAs using GO ‘biological
process’ categories. This analysis revealed that a set of abnor-
mally expressed miRNAs was associated with oncogenesis,
classical multidrug-resistance pathways and leukemic stem-
cell self-renewal and differentiation pathways. Our results
provide evidence for a link between relapse and the leukemic
stem-cell population; such a link has not previously been
reported in the context of DNA microarray analyses in
which signiﬁcant differences have been found in the expres-
sion of genes involved in cell-cycle regulation, DNA repair
and apoptosis (9–11).
Low miR-223 and miR-27a expression levels were detected
in diagnostic specimens from patients who subsequently
relapsed during the study. Furthermore, miR-223 had previously
been identiﬁed as an essential factor in myeloid lineage devel-
opment and as a putative tumor-suppressor gene in recurrent
ovarian cancer (35). Previous gene-expression proﬁling identi-
ﬁed a subset of T-cell ALL with myeloid-like genetic features
and miR-223 overexpression (36). Also, miR-223 has been
proposed to be an important factor in leukemogenesis (37);
therefore, we propose that its downregulation contributes to
the survival of leukemic cells.
We further determined that E2F1 was a target of miR-223 in
leukemic cells. E2F1 has a controversial role in cell-cycle
control,asitexhibitsadualbehavior:itcanactaseitheratumor-
suppressor or an oncogene. Therefore, we speculated that
miR-223 could be used as an indicator of leukemia relapse
mediated by E2F1. Another downregulated miRNA, miR-27a,
is involved in the carcinogenesis of several cancer types. Inter-
estingly, miR-27a exerts its oncogenic effects by regulating
ZBTB10, which results in the overexpression of Sp proteins
and Sp-dependent genes, which are important for cell survival
and angiogenesis (38,39). We previously found that miR-27a
is relevant to treatment outcome in vivo (21) and might be
involved in the relapse of both lymphocytic leukemia and
myeloid leukemia. This result suggests that downregulation of
miR-27a might promote ALL relapse by regulating genes in
classical drug or multi-drug resistance pathways.
The most notable ﬁnding from this study was that many of
the identiﬁed miRNAs and their target genes are implicated in
leukemic cell (including leukemic stem cell) development, dif-
ferentiation and activation. For example, the polycomb gene
BMI1 was identiﬁed as a bona ﬁde target of miR-27a in this
study. A number of studies have demonstrated that BMI1
plays an essential role in regulating self-renewing HSCs and
leukemia stem cells in humans. Deletion of BMI1 can inhibit
the self-renewal of tumor stem cells and prevent leukemia re-
currence (40). Taken together with the ﬁnding that miR-27a
targets the multi-drug resistance gene MDR1 (21), it seems
possible that miR-27a downregulation leads to the
Figure 6. miR-708 expression is associated with prednisone response, risk group and relapse in ALL subtypes. (A) Differentially expressed miR-708 in ALL
patients with varying responses to prednisone treatment. (B) miR-708 expression in different risk groups for ALL was conﬁrmed using qRT-PCR. (C) miR-708
expression pattern in different subtypes of ALL. Lower expression was observed in T-ALL. (D) Differential expression of miR-708 in samples with different
WBC counts before chemotherapy. (E) Differential expression of miR-708 at time of diagnosis in samples with different remission statuses (measured by
percentage of blast cells) after 15 days of chemotherapy.
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promote leukemic cell proliferation or drug resistance, leading
to leukemia recurrence. In addition, our results revealed that
FOXO3 is a direct target of miR-708. FOXO3 has been
reported to act as either an oncogene or a tumor suppressor
in leukemia (41,42). It has also been shown that FOXO3 tran-
scriptional activity is required to prevent B-chronic lympho-
cytic leukemia and chronic myelogenous leukemia (30,41).
We, therefore, hypothesize that high miR-708 expression
mediated by inhibition of FOXO3 is critical for switching
from leukemia remission to relapse. Interestingly, miR-708
showed different expression patterns between patients who
have relapse potential and those who are in relapse. The
MiR-708 level is low in high relapse risk patients at diagnosis,
while specimens of relapsed patients were measured the abun-
dance of miR-708. One possible reason for this phenomenon is
that miR-708 is critical for HSC self-renewal because it targets
FOXO3. FOXO3 has an essential role in the maintenance of
the leukemia-initiating cells (LICs) that drive the recurrence
of chronic myeloid leukemia (41). Low miR-708 levels in a
high-relapse risk patient might result in loss of control of
FOXO3 stem-cell self-renewal functionality. As a result, LIC
proliferation might be stimulated. The exact mechanism of
this phenomenon has yet to be deﬁned.
Another contribution of this study is the ﬁnding that some of
these relapse-associated miRNAs (miR-708, miR-27a and
miR-223) could potentially be used as biomarkers for predict-
ing RFS. We found that the expression proﬁles of the three
miRNA could yield highly accurate predictions of pediatric
ALL outcomes, especially when two or three miRNAs were
considered in combination. The sensitivity and speciﬁcity of
these miRNAs are comparable to those of mRNAs, such as
IKZF1 (the sensitivity and speciﬁcity of which are 90.1 and
65%, respectively) (43), IL-15 (56.7 and 55.5%) (44),
CASP8AP2 (75 and 79.4%) (45) and a 21-gene classiﬁer
(71.6 and 77.4%) (46). Our data indicated that miRNA proﬁles
could also be a novel and reliable indicator for the prediction
of pediatric ALL relapses. However, because we did not
measure mRNA expression and we do not have miRNA and
mRNA data for the same samples, we could not address
whether the miRNA data add anything to the mRNA data pre-
dictions. Further research will be needed to assess whether
miRNA information adds predictive value or whether integrat-
ing information from both mRNA and miRNA proﬁles could
improve the accuracy of predicting clinical ALL relapse.
In conclusion, our study reports the miRNA proﬁles from
diagnosis, relapse and CR leukemia samples. To our knowl-
edge, this report is the ﬁrst to show that ALL relapse might
be mediated by miRNA deregulation. The existence of ALL
relapse-associated miRNAs provides new insight into the
molecular mechanisms of leukemia relapse such as that
relapse may be triggered as a consequence of therapy-induced
miRNA dysregulation. We also demonstrated, for the ﬁrst
time, that some relapse-associated miRNAs that correlated
with the RFS rate of childhood ALL, such as miR-708,
miR-27a and miR-223, could be used to predict the risk of
relapse before patients undergo therapy. These
relapse-associated miRNAs and their targets might also be
used to optimize anti-leukemia therapy and might be novel
targets for the development of new leukemia countermeasures.
PATIENTS, MATERIALS AND METHODS
Patients and samples
Bone marrow samples were obtained from 18 patients where
matched samples at initial diagnosis and ﬁrst marrow relapse
or CR were available. The majority of patients had a
B-precursor phenotype (n ¼ 11) and six patients had T-cell
ALL (T-ALL; Table 2). These patients were treated according
to the modiﬁed ALLIC BFM 2002 protocol. Patient character-
istics are detailed in Table 2. An independent set of 104
marrow samples acquired at the time of initial diagnosis and
29 samples acquired at relapse were used to conﬁrm the differ-
ential miRNA expression pattern and target gene expression
by qRT-PCR. ALL samples were enrolled at the First and
Second Afﬁliated Hospital of Sun Yat-sen University or
Beijing Children’s Hospital. Written informed consent was
obtained from the parent/guardians. The study was approved
by the ethics committee of the afﬁliated hospitals of Sun
Yat-sen University.
Table 2. Pediatric ALL patients’ characteristics
Type of sample Characteristics Median (range) No. (%)
Initial diagnosed
(N ¼ 122)
Age at diagnosis,
years
6.0 (0.25–14.5)
Sex
Male 75 (61.5)
Female 47 (38.5)
WBC count, ×10
9
per l
21.7 (1.7–557.6)
Less than 20 60 (49.2)
20 or higher 62 (50.8)
FAB
L1 32 (26.2)
L2 64 (52.4)
L3 8 (6.6)
N/A 18 (14.8)
Risk group
HR 42 (34.4)
MR 46 (37.7)
SR 23 (18.9)
N/A 11 (9.0)
Prednisone response
Good response 77 (63.1)
Poor response 26 (21.3)
N/A 19 (15.6)
Immunophenotype
B 92 (75.4)
T 20 (16.4)
N/A 10 (8.2)
Cytogenetics
BCR–ABLpositive 8 (6.6)
BCR–ABL
negative
114 (93.4)
MLL positive 6 (4.9)
MLL negative 116 (95.1)
After therapy (N ¼ 77) CR
a 40
Relapse
b 37
Normal (N ¼ 10)
aCR samples are from 40 initial diagnosed patients with 3 years clinical
follow-up.
bRelapse samples contain eight matched samples from initial diagnosis.
4912 Human Molecular Genetics, 2011, Vol. 20, No. 24Cell lines and cell cultures
The human Jurkat leukemic T-cell line was cultured in
RPMI-1640 medium (HyClone, UT, USA), and the
HEK-293T cell line derived from human embryonic kidney
was grown in DMEM medium (Invitrogen, Carlsbad, CA,
USA) supplemented with 10% fetal bovine serum (HyClone)
at 378C in a 5% CO2 atmosphere.
RNA isolation and miRNA microarray proﬁling
Total RNA was extracted from patient samples with TRIzol
(Invitrogen) according to the manufacturer’s instructions.
miRNA microarray analysis was performed with the Affyme-
trix miRNA microarray platform (Capital Bio, Beijing,
China), containing 743 probes in triplicate corresponding to
576 human (including 122 predicted miRNAs sequences
from the published reference), 238 rat and 358 mouse
mature miRNAs found in the miRNA Registry (http://
microrna.sanger.ac.uk/sequences/; miRBase16; September
2010). Each sample was analyzed in triplicate.
The miRNA detection signal threshold was deﬁned as twice
the maximum background signal, and the maximum signal
level of the background probes was 180. Normalization was
performed using a cyclic LOWESS (locally weighted regres-
sion) method to remove the system-related variations. The
data adjustments included data ﬁltering, log2 transformation,
gene centering and normalization. Diagnosis and relapse or
CR samples were compared using t-test, and miRNAs with P
, 0.05 were considered signiﬁcant for cluster analysis. The
cluster analysis was performed using a hierarchical method
with average linkage and Euclidean distance metrics. All the
data are MIAME compliant and the raw data are being depos-
ited in a MIAME compliant database (ArrayExpress, GEO).
Quantitative real-time PCR analysis
qRT-PCR was performed to detect mature miRNAs. Brieﬂy,
0.2 mg of small RNA extracted from patient samples was
reverse transcribed to cDNA using M-MLV reverse transcript-
ase (Promega, WI, USA) and ampliﬁed with speciﬁc miRNA
RT primers and PCR ampliﬁcation primers (Sangon, Shang-
hai, China). All primer sequences are shown in Supplementary
Material, Table S3. The expression level of each miRNA was
determined using the 2
2DeltaDeltaCt method. The results are pre-
sented as the fold change of each miRNA in the patient
samples relative to the normal control samples.
Statistical analysis
Correlations were determined using the Pearson correlation
coefﬁcient (r), and a Fisher r-to-z transformation was per-
formed to calculate a probability level (P-value). The mean
time to ﬁrst relapse was compared between groups using the
rank sum test. Analysis of RFS—deﬁned as the time from
CR to relapse—was performed according to the Kaplan–
Meier method, and comparisons of outcomes between sub-
groups were performed by using the log-rank test. Two-tailed
tests were used for univariate comparisons. For univariate and
multivariate analysis of prognostic factors, a Cox proportional
hazard regression model was used. Accuracies, sensitivity,
speciﬁcity, positive predictive values (the proportion of
patients among those predicted to relapse who actually
relapsed) and negative predictive values (the proportion of
patients among those predicted to be non-relapsers who did
not relapse within 3 years) were validated. In the combination
of three miRNA models, patients with low expression of all
three miRNAs were predicted to relapse, and in the combin-
ation of two of three miRNA models, patients with low
expression of at least two miRNAs were predicted to relapse.
GO analysis of miRNA targets
Three complementary websites were used for GO analysis of
miRNA targets. MiRNA predicted target was download from
TargetScan website. For GO analysis, GO (47) terms and
gene information were downloaded from the NCBI website
(ftp://ftp.ncbi.nih.gov/gene/DATA) on November 20, 2010.
The biological processes and molecular functions categories,
as deﬁned in the Gene Ontology Consortium database (http://
www.geneontology.org) (47), were analyzed, and 395 genes
(see Supplementary Material, Table S2) were predicted as the
targets of miRNAs output by GO analysis. Signiﬁcant over-
representation of particular GO terms in the data set was deter-
mined using the software GeneMerge with corrections for
multiple tests (48). Bonferroni-corrected P-values are reported,
and a cutoff of 0.1 on the Bonferroni-corrected P-value was
applied. Bonferroni-corrected P-values for overrepresented
GO terms for each miRNA target were plotted on a negative
log2scale(e.g.P-values2
0 ¼ 1,2
26 ¼ 0.015625)(24).Weper-
formed two-way hierarchical clustering with the program MeV
(49) using the Pearson correlation coefﬁcient and average
linkage clustering. To evaluate the functional signiﬁcance of
the miRNA target genes, we considered the GO distribution
ofallhumangenesasthebackgroundandthenemployedafunc-
tional enrichment analysis against GO biological process terms
database. According to previous studies (50), over-represented
functional themes present in background were mapped on the
GO hierarchy using a Cytoscape’s (26) plugin BINGO (25). A
binomial distribution statistical testing method was selected
andasigniﬁcancelevelof0.1wasapplied.Formultiplehypoth-
eses testing, the Benjamini and Hochberg false discovery rate
correction (51) was applied to reduce false negatives at the
cost of a few more false positives. We only selected GO terms
which are associated with our current study to draw ﬁgure.
Cell transfection and vector constructs
The miR-708, miR-223 and miR-27a mimics and scrambled oli-
gonucleotides (named as miR-NC, the negative control) were
purchased from GenePharm (Shanghai, China). The miR-708
antisense was purchased from RiboBio (Guangzhou, China).
Jurkat cell were electrotransfected with mimics or miRNA anti-
sense at a ﬁnal concentration of 100 nM, and HEK-293T cell was
transfected with mimics or miR-NC using Lipofectamine 2000
(Invitrogen). The transfected cells were collected to exact
protein for western blot at 48 h after post-transfection.
TheMREinthe3′UTRsegmentsofFOXO3,BMI1andE2F1
containing putative binding sites to their respective miRNA
were synthesized by Songon (Shanghai, China) and insert into
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psiCHECK-2-FOXO3, psiCHECK-2-BMI1 and psiCHECK-2-
E2F1, were used for miRNA functional analysis. The deletion
mutant reporter constructs psiCHECK-2-FOXO3-M, psi-
CHECK-2-BMI1-M and psiCHECK-2-E2F1-M, in which the
sites of perfect complementarity to miRNAs were deleted
from parent constructs. Wild-type and mutant insertions were
conﬁrmed by DNA sequencing. All primers information is
available in Supplementary Material, Table S3.
Target prediction and luciferase reporter assay
Three prediction algorithms PicTar (http://pictar.mdc-berlin.
de/, New York University and Max Delbruck Centrum),
miRanda (http://cbio.mskcc.org/mirnaviewer/, Memorial
Sloan-Kettering Cancer Center) and TargetScan (http://www.
targetscan.org/, Whitehead Institute for Biomedical Research)
were used to identify possible targets of four miRNAs,
miR-27a, miR-128b, miR-223 and miR-708. For luciferase
reporter experiments, HEK-293T cells were transfected with
each 3′UTR luciferase construct using Lipofectamine 2000
(Invitrogen) according to the manufacturer’s instructions.
Each experiment was repeated at least three times. A statistical
comparison of the luciferase results was performed with a two-
tailed t test with the Bonferroni correction, and P , 0.05 was
considered signiﬁcant. Jurkat cell lines were transfected by
Lipofectamine 2000 (Invitrogen) following the manufacturer’s
instructions. Luciferase activities were measured at 48 and
72 h after transfection using dual-luciferase assays (Promega).
Western blot
Cells were collected 48 and 72 h after transfection. Total cel-
lular extracts were prepared by homogenization of 5 × 10
6
cells. Lysates were incubated at 48C for 30 min. followed by
centrifugation at 15 700g at 48C for 30 min. Equal amounts
of proteins (2 mg) and 10 ml loading control (Fermentas)
were separated by 8% SDS–PAGE and transferred to polyvi-
nylidene diﬂuoride membranes (GE Healthcare Biosciences).
The membranes were incubated with antibodies against
FOXO3 (Millipore, MA, USA). Antibody binding was
assessed by incubation with horseradish peroxidase-
conjugated antimouse secondary antibodies (Santa Cruz Bio-
technology), BMI1 (Cell Signaling Technologies, Beverly,
MA, USA) and E2F1 (Upstate, MA, USA). Chemilumines-
cence was detected using an ECL Plus immunoblotting
detection system (GE Healthcare Biosciences).
SUPPLEMENTARY MATERIAL
Supplementary Material is available at HMG online.
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